Avidity Partners 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 43 US equity positions worth $439.4m in its Q3 2025 13F filing. The largest position was DNTH at 28.7% of the reported book, followed by CGON and MDT. Against the Q2 2025 filing, it opened 13 new positions, added to 8 and reduced 20 among the top 43 holdings.
What did Avidity Partners own in Q3 2025? Top 43 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 28.7% | $126.1m | 3,204,184 | 84% | added |
| 2 | CGON CG ONCOLOGY INC | Healthcare | 14.7% | $64.5m | 1,600,899 | 7% | added |
| 3 | MDT MEDTRONIC PLC | Healthcare | 4.1% | $18.2m | 190,600 | – | new |
| 4 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 3.7% | $16.0m | 164,300 | -49% | reduced |
| 5 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.9% | $12.7m | 660,424 | 88% | added |
| 6 | BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 2.6% | $11.6m | 257,600 | – | new |
| 7 | NTRA NATERA INC | Healthcare | 2.6% | $11.3m | 70,400 | -65% | reduced |
| 8 | DHR DANAHER CORPORATION | Healthcare | 2.5% | $10.8m | 54,700 | -39% | reduced |
| 9 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 2.3% | $10.3m | 510,000 | -26% | reduced |
| 10 | CATX PERSPECTIVE THERAPEUTICS INC | 2.3% | $10.3m | 2,994,033 | 61% | added | |
| 11 | JBIO JADE BIOSCIENCES INC | 2.2% | $9.7m | 1,127,186 | 0% | held | |
| 12 | PFE PFIZER INC | Healthcare | 2.1% | $9.3m | 366,400 | – | new |
| 13 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 2.1% | $9.2m | 18,900 | -36% | reduced |
| 14 | CNTX CONTEXT THERAPEUTICS INC | 2.0% | $8.7m | 8,981,855 | 20% | added | |
| 15 | GMAB GENMAB A/S | Healthcare | 1.7% | $7.6m | 248,100 | -62% | reduced |
| 16 | METSERA INC | 1.7% | $7.4m | 140,500 | – | new | |
| 17 | UNH UNITEDHEALTH GROUP INC | Healthcare | 1.4% | $6.1m | 17,800 | -44% | reduced |
| 18 | ARVN ARVINAS INC | Healthcare | 1.4% | $6.0m | 698,363 | 187% | added |
| 19 | COR CENCORA INC | Healthcare | 1.4% | $5.9m | 19,000 | -42% | reduced |
| 20 | EHC ENCOMPASS HEALTH CORP | Healthcare | 1.2% | $5.3m | 41,900 | -43% | reduced |
| 21 | JNJ JOHNSON & JOHNSON | Healthcare | 1.1% | $5.0m | 26,800 | – | new |
| 22 | CI THE CIGNA GROUP | Healthcare | 1.1% | $4.8m | 16,600 | – | new |
| 23 | ABBV ABBVIE INC | Healthcare | 1.0% | $4.6m | 19,800 | – | new |
| 24 | MCK MCKESSON CORP | Healthcare | 1.0% | $4.5m | 5,800 | -57% | reduced |
| 25 | CARL CARLSMED INC | 1.0% | $4.3m | 321,912 | – | new | |
| 26 | KVUE KENVUE INC | Consumer Defensive | 1.0% | $4.3m | 265,200 | – | new |
| 27 | IMUX IMMUNIC INC | Healthcare | 0.9% | $4.1m | 4,699,411 | -16% | reduced |
| 28 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 0.9% | $4.0m | 214,400 | -20% | reduced |
| 29 | EXK EXACT SCIENCES CORP | Basic Materials | 0.9% | $4.0m | 73,600 | -79% | reduced |
| 30 | PHAT PHATHOM PHARMACEUTICALS INC | 0.8% | $3.6m | 306,000 | -71% | reduced | |
| 31 | RGEN REPLIGEN CORP | Healthcare | 0.7% | $3.1m | 23,300 | -78% | reduced |
| 32 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 0.7% | $3.1m | 144,000 | – | new |
| 33 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.7% | $2.9m | 14,500 | – | new |
| 34 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.7% | $2.9m | 140,300 | 1142% | added |
| 35 | BEAM BEAM THERAPEUTICS INC | Healthcare | 0.6% | $2.7m | 112,000 | -73% | reduced |
| 36 | SCYX SCYNEXIS INC | 0.6% | $2.6m | 3,350,528 | 173% | added | |
| 37 | HQY HEALTHEQUITY INC | Healthcare | 0.5% | $2.4m | 25,300 | -72% | reduced |
| 38 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 0.5% | $2.2m | 297,500 | – | new |
| 39 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.5% | $2.1m | 53,400 | -51% | reduced |
| 40 | AKERO THERAPEUTICS INC | 0.4% | $1.9m | 40,500 | -70% | reduced | |
| 41 | INSM INSMED INC | Healthcare | 0.4% | $1.7m | 11,600 | -80% | reduced |
| 42 | KPTI KARYOPHARM THERAPEUTICS INC | 0.2% | $880.1k | 134,566 | 0% | held | |
| 43 | IMRX IMMUNEERING CORP | 0.1% | $636.3k | 90,900 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.